Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Landgren on Daratumumab Triplet in Relapsed Myeloma

C. Ola Landgren, MD, PhD
Published: Wednesday, Jan 18, 2017



C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the daratumumab (Darzalex) triplets in the treatment of patients with relapsed multiple myeloma.

In trials with 2-drug combinations versus 3-drug combination, the latter has shown more substantial results in relapsed myeloma, says Landgren.

Daratumumab was recently approved to be used in combination with bortezomib (Velcade) plus dexamethasone, or lenalidomide (Revlimid) plus dexamethasone as treatment for patients with multiple myeloma who have had at least 1 prior therapy—which is ideal for patients with relapsed myeloma who have had anywhere from 1 to 3 prior therapies.

According to Landgren, these combinations with daratumumab are going to change the landscape for the treatment of relapsed myeloma.
 


C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the daratumumab (Darzalex) triplets in the treatment of patients with relapsed multiple myeloma.

In trials with 2-drug combinations versus 3-drug combination, the latter has shown more substantial results in relapsed myeloma, says Landgren.

Daratumumab was recently approved to be used in combination with bortezomib (Velcade) plus dexamethasone, or lenalidomide (Revlimid) plus dexamethasone as treatment for patients with multiple myeloma who have had at least 1 prior therapy—which is ideal for patients with relapsed myeloma who have had anywhere from 1 to 3 prior therapies.

According to Landgren, these combinations with daratumumab are going to change the landscape for the treatment of relapsed myeloma.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x